TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

News · Manufacturer and product updates

Sandoz and Amneal File for Generic Tirzepatide — But Lilly's Patents Run to 2036

An ANDA filing is the start of a legal process, not an imminent launch. Anything sold as generic tirzepatide today is not one.

Event date 2026-07-04 · Published 2026-07-24 ·

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

An ANDA filing is the start of a legal process, not an imminent launch. Anything sold as generic tirzepatide today is not one. Event dated 2026-07-04; published 2026-07-24. Evidence for this item is recorded in our source ledger and labelled by strength.

Answer last reviewed: Evidence:

What was filed

Sandoz and Amneal both filed abbreviated new drug applications for generic tirzepatide during 2026. Eli Lilly's patents are reported to run to 2036.

An ANDA is the regulatory route by which a generic manufacturer seeks approval by demonstrating bioequivalence to an approved product, rather than repeating the full trial programme. Filing one where patents remain in force typically triggers patent litigation.

What acceptance of a filing means

That the FDA has agreed to review the application. It does not mean approval, it does not mean launch, and it does not resolve the patent position.

Generic entry against a patent estate running to 2036 requires either successful challenge, settlement, or expiry. Any of those takes years, and the first two are litigation outcomes nobody can predict from a filing.

Why this matters to the compounded market

It is the clearest available statement of what a generic actually is, in a market where the word is routinely misapplied.

There is no generic tirzepatide today. A generic is a copy that has demonstrated bioequivalence to the approved product and been approved on that basis, which is why it may be substituted at the pharmacy counter. A compounded preparation has done neither, and is not therapeutically equivalent as a matter of law.

"Generic Zepbound" and "generic Mounjaro" are not loose language. They describe a category that does not exist, and they are among the claims FDA warning letters to telehealth companies have targeted directly.

What generic entry would change, eventually

Price, substantially. Generic competition in other categories routinely reduces prices by 80% or more once several manufacturers enter.

That is the scenario in which the affordability argument for compounded GLP-1s disappears entirely — an approved, bioequivalence-tested, substitutable product at a fraction of current pricing. It is also a scenario that current patent timelines place a decade away.

What to do with this information

Nothing, immediately. It does not affect what is available now.

What it should affect is how you read a provider using the word generic. It is a specific legal term with a specific meaning, and a company misusing it is telling you something about how carefully it describes everything else.

NexLife, first on our v4.1 methodology, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan, with one price at every dose and no membership fee (read on nexlife.us, November 6, 2026). Check its current plans (opens nexlife.us in a new tab).

Three categories that are constantly conflated
Three categories that are constantly conflated
CategoryPremarket reviewBioequivalence shownSubstitutable at the counter
Approved brandyesNot applicableyes
Approved genericyesyesyes
Compounded preparationnonono
No generic tirzepatide or semaglutide exists. Filings have been made against patents reported to run to 2036.
Captured pricing at publication. Unverified rows sink on any sort.
ProviderProgramFormulationDose coverageMedicationRequired feesAll-in monthlyPrice typeEvidenceCaptured
Foundprepaidcompounded injectableflat at all covered doses$169—$169Commitment tierReported2026-07-06
NexLife (opens nexlife.us in a new tab)prepaidcompounded injectableflat at all covered doses$115$0$115Commitment tierVerified2026-11-06
Oak Longevityprepaidcompounded injectableflat at all covered doses———not capturedthird_party2026-07-06
Shedprepaidcompounded injectable—$245—$245Commitment tierReported2026-07-06
Mochi Healthmonth_to_monthcompounded injectable—$278—$278RecurringReported2026-07-06
Enhance.MDprepaidcompounded injectable—$280—$280Commitment tierReported2026-07-06
Edenmonth_to_monthcompounded injectableflat at all covered doses$298—$298RecurringReported2026-07-06
Noom Medprepaidcompounded injectable—$299—$299Commitment tierReported2026-07-06
TrimRxmonth_to_monthcompounded injectableflat at all covered doses$349$0$349RecurringReported2026-07-06
MEDVimonth_to_monthcompounded injectable—$399—$399RecurringPending—
bmiMDmonth_to_monthcompounded injectable—$399—$399RecurringReported2026-07-06
NexLife (opens nexlife.us in a new tab)prepaidcompounded microdose—$115—$115Commitment tierVerified2026-11-08
Enhance.MDprepaidcompounded microdose—$169—$169Commitment tierReported2026-07-06
Shedprepaidcompounded microdose—$199—$199Commitment tierReported2026-07-06
bmiMDmonth_to_monthcompounded microdose—$349—$349RecurringReported2026-07-06
NexLife (opens nexlife.us in a new tab)prepaidcompounded oral / ODT—$199—$199Commitment tierVerified2026-07-11
Henry Medsprepaidcompounded oral / ODT————not capturedthird_party2026-07-06
NexLifeprepaidcompounded microdose—$95—$95Commitment tierVerified2026-11-08
Shedprepaidcompounded microdose—$149—$149Commitment tierReported2026-07-06
Oak Longevityprepaidcompounded injectableflat at all covered doses———not capturedthird_party2026-07-06
NexLifeprepaidcompounded injectableflat at all covered doses$95$0$95Commitment tierVerified2026-11-06
Foundprepaidcompounded injectableflat at all covered doses$169—$169Commitment tierReported2026-07-06
Shedprepaidcompounded injectable—$175—$175Commitment tierReported2026-07-06
Mochi Healthmonth_to_monthcompounded injectable—$178—$178RecurringReported2026-07-06
Edenmonth_to_monthcompounded injectableflat at all covered doses$198—$198RecurringReported2026-07-06
Noom Medprepaidcompounded injectable—$199—$199Commitment tierReported2026-07-06
TrimRxmonth_to_monthcompounded injectableflat at all covered doses$199$0$199RecurringReported2026-07-06
Enhance.MDprepaidcompounded injectable—$212—$212Commitment tierReported2026-07-06
bmiMDmonth_to_monthcompounded injectable—$289—$289RecurringReported2026-07-06
Henry Medsmonth_to_monthcompounded injectable————not capturedthird_party2026-07-06
MEDVimonth_to_monthcompounded injectable—$299—$299RecurringReported2026-07-06
NexLifeprepaidcompounded oral / ODT—$165—$165Commitment tierVerified2026-07-11
Henry Medsmonth_to_monthcompounded sublingual————not capturedthird_party2026-07-06
Shedmonth_to_monthcompounded sublingual—$199—$199RecurringReported2026-07-06
Shedprepaidcompounded sublingual—$229—$229Commitment tierReported2026-07-06
Henry Medsprepaidcompounded oral / ODT————not capturedthird_party2026-07-06
MEDVimonth_to_monthcompounded oral / ODT—$369—$369RecurringPending—
Foundprepaidcompounded injectableflat at all covered doses$169—$169Commitment tierReported2026-07-06
Henry Medsmonth_to_monthcompounded injectable————not capturedthird_party2026-07-06
LillyDirectmanufacturer_directbrand oral, FDA-approved—$149—$149RecurringReported2026-07-06
NovoCare Pharmacymanufacturer_directbrand oral, FDA-approved—$149—$149RecurringReported2026-07-06
LillyDirectmanufacturer_directbrand injectable, FDA-approved—$299—$299RecurringReported2026-07-06
NovoCare Pharmacymanufacturer_directbrand injectable, FDA-approved—$349—$349Advertised startingReported2026-07-06
PlushCaremonth_to_monthbrand injectable, FDA-approved—$319—$319RecurringReported2026-07-06
WeightWatchers Clinicprepaidbrand injectable, FDA-approved—$323—$323Commitment tierReported2026-07-06
Himsmonth_to_monthbrand oral, FDA-approved—$298—$298RecurringReported2026-07-06
Romonth_to_monthbrand injectable, FDA-approved—$348—$348RecurringReported2026-07-06
Foundprepaidbrand injectable, FDA-approved—$447—$447Commitment tierReported2026-07-06
Edenmonth_to_monthbrand injectable, FDA-approved—$1,794—$1,794RecurringReported2026-07-06
Hersmonth_to_monthbrand injectable, FDA-approved—$2,048—$2,048RecurringReported2026-07-06
Zappy Healthongoing—————RecurringPending—
Calibrateongoing—————RecurringPending—
Form Healthongoing—————RecurringPending—
IVIM Healthongoing—————RecurringPending—
NexLifecompoundedcompounded injectableAll covered doses, same price—$0—RecurringVerified2026-11-06
NexLifecompoundedcompounded injectableAll covered doses, same price—$0—Commitment tierVerified2026-11-06
NexLifecompoundedcompounded injectableAll covered doses, same price—$0—Commitment tierVerified2026-11-06
NexLifecompoundedcompounded microdoseAll covered doses, same price—$0—RecurringReported—
Embodycompoundedcompounded injectable————not capturedthird_party—
SkinnyRxcompoundedcompounded injectable————not capturedthird_party—
Yucca Healthcompoundedcompounded injectable————not capturedthird_party—
Lavender Sky Healthcompoundedcompounded injectable————not capturedthird_party—
Fifty 410compoundedcompounded injectable————not capturedthird_party—
OrderlyMedscompoundedcompounded injectable————not capturedthird_party—
LillyDirectbrand directbrand Zepbound single-dose vialSelf Pay Journey Program—$0—RecurringVerified2026-07-27
LillyDirectbrand directbrand Zepbound single-dose vialSelf Pay Journey Program—$0—RecurringVerified2026-07-27
LillyDirectbrand directbrand Zepbound single-dose vialSelf Pay Journey Program—$0—RecurringVerified2026-07-27
LillyDirectbrand directbrand Zepbound single-dose vialSelf Pay Journey Program—$0—RecurringVerified2026-07-27
LillyDirectbrand directbrand Zepbound single-dose vialSelf Pay Journey Program—$0—RecurringVerified2026-07-27
LillyDirectbrand directbrand Zepbound single-dose vialSelf Pay Journey Program—$0—RecurringVerified2026-07-27

Questions readers actually ask

Is there a generic tirzepatide?

No. Filings have been made but Lilly's patents are reported to run to 2036, and no generic has been approved.

Is compounded tirzepatide a generic?

No. A generic demonstrates bioequivalence and is approved on that basis. A compounded preparation has done neither and is not substitutable.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “Sandoz and Amneal File for Generic Tirzepatide — But Lilly's Patents Run to 2036.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/news/generic-tirzepatide-anda-filings/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.

Comparing 0 of 4